Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage.
D000614:Aminocaproates / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001510:Bed Rest; D002555:Cerebrospinal Fluid / Q000502:physiology; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D006849:Hydrocephalus / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D002532:Intracranial Aneurysm / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D002546:Ischemic Attack, Transient / Q000150:complications; D009135:Muscular Diseases / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid